7ZCF
SARS-CoV-2 Spike RBD in complex with the single chain fragment scFv76 (Focused Refinement)
Summary for 7ZCF
Entry DOI | 10.2210/pdb7zcf/pdb |
EMDB information | 14629 |
Descriptor | Spike glycoprotein,Fibritin, scFv76 single chain fragment, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total) |
Functional Keywords | sars-cov-2, spike, single chain fragment, viral protein |
Biological source | Severe acute respiratory syndrome coronavirus 2 More |
Total number of polymer chains | 2 |
Total formula weight | 170689.59 |
Authors | Chaves-Sanjuan, A.,Bolognesi, M. (deposition date: 2022-03-28, release date: 2022-10-12, Last modification date: 2024-11-13) |
Primary citation | Milazzo, F.M.,Chaves-Sanjuan, A.,Minenkova, O.,Santapaola, D.,Anastasi, A.M.,Battistuzzi, G.,Chiapparino, C.,Rosi, A.,Merlo Pich, E.,Albertoni, C.,Marra, E.,Luberto, L.,Viollet, C.,Spagnoli, L.G.,Riccio, A.,Rossi, A.,Santoro, M.G.,Ballabio, F.,Paissoni, C.,Camilloni, C.,Bolognesi, M.,De Santis, R. Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery. Mol.Ther., 31:362-373, 2022 Cited by PubMed Abstract: The uneven worldwide vaccination coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and emergence of variants escaping immunity call for broadly effective and easily deployable therapeutic agents. We have previously described the human single-chain scFv76 antibody, which recognizes SARS-CoV-2 Alpha, Beta, Gamma and Delta variants. We now show that scFv76 also neutralizes the infectivity and fusogenic activity of the Omicron BA.1 and BA.2 variants. Cryoelectron microscopy (cryo-EM) analysis reveals that scFv76 binds to a well-conserved SARS-CoV-2 spike epitope, providing the structural basis for its broad-spectrum activity. We demonstrate that nebulized scFv76 has therapeutic efficacy in a severe hACE2 transgenic mouse model of coronavirus disease 2019 (COVID-19) pneumonia, as shown by body weight and pulmonary viral load data. Counteraction of infection correlates with inhibition of lung inflammation, as observed by histopathology and expression of inflammatory cytokines and chemokines. Biomarkers of pulmonary endothelial damage were also significantly reduced in scFv76-treated mice. The results support use of nebulized scFv76 for COVID-19 induced by any SARS-CoV-2 variants that have emerged so far. PubMed: 36114671DOI: 10.1016/j.ymthe.2022.09.010 PDB entries with the same primary citation |
Experimental method | ELECTRON MICROSCOPY (4 Å) |
Structure validation
Download full validation report
